
USD
$0.00
(0.00%
)At Close (As of Dec 11, 2025)
$257.66M
Market Cap
-
P/E Ratio
-0.5
EPS
$2.54
52 Week High
$0.62
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$59M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $6.4M |
| Capital Expenditures | $2.1M |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | $66M |
| Cashflow From Financing | $1.1M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $524K |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$71M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Nautilus Biotechnology Inc. is an innovative life sciences company based in Seattle, Washington, focused on revolutionizing proteomics through its state-of-the-art platform technology. As a development-stage enterprise, Nautilus is committed to advancing the understanding of protein dynamics, essential for uncovering biological mechanisms and disease pathways. By tackling the complexities of the proteome, the company aims to drive advancements in drug discovery and personalized medicine, catering to the growing need for targeted therapeutic approaches in today’s healthcare landscape.